Cargando…

The Psychosocial Screen for Cancer (PSSCAN): Further validation and normative data

BACKGROUND: We have previously reported on the development of a cancer-specific screening instrument for anxiety and depression (PSSCAN). No information on cut-off scores or their meaning for diagnosis was available when PSSCAN was first described. Needed were additional analyses to recommend empiri...

Descripción completa

Detalles Bibliográficos
Autores principales: Linden, Wolfgang, Andrea Vodermaier, A, McKenzie, Regina, Barroetavena, Maria C, Yi, Dahyun, Doll, Richard
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651864/
https://www.ncbi.nlm.nih.gov/pubmed/19239709
http://dx.doi.org/10.1186/1477-7525-7-16
_version_ 1782165199194685440
author Linden, Wolfgang
Andrea Vodermaier, A
McKenzie, Regina
Barroetavena, Maria C
Yi, Dahyun
Doll, Richard
author_facet Linden, Wolfgang
Andrea Vodermaier, A
McKenzie, Regina
Barroetavena, Maria C
Yi, Dahyun
Doll, Richard
author_sort Linden, Wolfgang
collection PubMed
description BACKGROUND: We have previously reported on the development of a cancer-specific screening instrument for anxiety and depression (PSSCAN). No information on cut-off scores or their meaning for diagnosis was available when PSSCAN was first described. Needed were additional analyses to recommend empirically justified cut-off scores as well as data norms for healthy adult samples so as to lend meaning to the recommended cut-off scores. METHODS: We computed sensitivity/specificity indices based on a sample of 101 cancer patients who had provided PSSCAN data on anxiety and depression and who had completed another standardized instrument with strong psychometrics. Next, we compared mean scores for four samples with known differences in health status, a healthy community sample (n = 561), a sample of patients with a representative mix of cancer subtypes (n = 570), a more severely ill sample of in-patients with cancer (n = 78), and a community sample with a chronic illness other than cancer (n = 85). RESULTS: Sensitivity/specificity analyses revealed that an excellent balance of sensitivity/specificity was achievable with 92%/98% respectively for clinical anxiety and 100% and 86% respectively for clinical depression. Newly diagnosed patients with cancer were no more anxious than healthy community controls but showed elevations in depression scores. Both, patients with chronic illness other than cancer and those with longer-standing cancer diagnoses revealed greater levels of distress than newly diagnosed cancer patients or healthy adult controls. CONCLUSION: These additional data on criterion validity and community versus patient norms for PSSCAN serve to enhance its utility for clinical practice.
format Text
id pubmed-2651864
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26518642009-03-06 The Psychosocial Screen for Cancer (PSSCAN): Further validation and normative data Linden, Wolfgang Andrea Vodermaier, A McKenzie, Regina Barroetavena, Maria C Yi, Dahyun Doll, Richard Health Qual Life Outcomes Research BACKGROUND: We have previously reported on the development of a cancer-specific screening instrument for anxiety and depression (PSSCAN). No information on cut-off scores or their meaning for diagnosis was available when PSSCAN was first described. Needed were additional analyses to recommend empirically justified cut-off scores as well as data norms for healthy adult samples so as to lend meaning to the recommended cut-off scores. METHODS: We computed sensitivity/specificity indices based on a sample of 101 cancer patients who had provided PSSCAN data on anxiety and depression and who had completed another standardized instrument with strong psychometrics. Next, we compared mean scores for four samples with known differences in health status, a healthy community sample (n = 561), a sample of patients with a representative mix of cancer subtypes (n = 570), a more severely ill sample of in-patients with cancer (n = 78), and a community sample with a chronic illness other than cancer (n = 85). RESULTS: Sensitivity/specificity analyses revealed that an excellent balance of sensitivity/specificity was achievable with 92%/98% respectively for clinical anxiety and 100% and 86% respectively for clinical depression. Newly diagnosed patients with cancer were no more anxious than healthy community controls but showed elevations in depression scores. Both, patients with chronic illness other than cancer and those with longer-standing cancer diagnoses revealed greater levels of distress than newly diagnosed cancer patients or healthy adult controls. CONCLUSION: These additional data on criterion validity and community versus patient norms for PSSCAN serve to enhance its utility for clinical practice. BioMed Central 2009-02-24 /pmc/articles/PMC2651864/ /pubmed/19239709 http://dx.doi.org/10.1186/1477-7525-7-16 Text en Copyright © 2009 Linden et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Linden, Wolfgang
Andrea Vodermaier, A
McKenzie, Regina
Barroetavena, Maria C
Yi, Dahyun
Doll, Richard
The Psychosocial Screen for Cancer (PSSCAN): Further validation and normative data
title The Psychosocial Screen for Cancer (PSSCAN): Further validation and normative data
title_full The Psychosocial Screen for Cancer (PSSCAN): Further validation and normative data
title_fullStr The Psychosocial Screen for Cancer (PSSCAN): Further validation and normative data
title_full_unstemmed The Psychosocial Screen for Cancer (PSSCAN): Further validation and normative data
title_short The Psychosocial Screen for Cancer (PSSCAN): Further validation and normative data
title_sort psychosocial screen for cancer (psscan): further validation and normative data
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651864/
https://www.ncbi.nlm.nih.gov/pubmed/19239709
http://dx.doi.org/10.1186/1477-7525-7-16
work_keys_str_mv AT lindenwolfgang thepsychosocialscreenforcancerpsscanfurthervalidationandnormativedata
AT andreavodermaiera thepsychosocialscreenforcancerpsscanfurthervalidationandnormativedata
AT mckenzieregina thepsychosocialscreenforcancerpsscanfurthervalidationandnormativedata
AT barroetavenamariac thepsychosocialscreenforcancerpsscanfurthervalidationandnormativedata
AT yidahyun thepsychosocialscreenforcancerpsscanfurthervalidationandnormativedata
AT dollrichard thepsychosocialscreenforcancerpsscanfurthervalidationandnormativedata
AT lindenwolfgang psychosocialscreenforcancerpsscanfurthervalidationandnormativedata
AT andreavodermaiera psychosocialscreenforcancerpsscanfurthervalidationandnormativedata
AT mckenzieregina psychosocialscreenforcancerpsscanfurthervalidationandnormativedata
AT barroetavenamariac psychosocialscreenforcancerpsscanfurthervalidationandnormativedata
AT yidahyun psychosocialscreenforcancerpsscanfurthervalidationandnormativedata
AT dollrichard psychosocialscreenforcancerpsscanfurthervalidationandnormativedata